Table 2—

Comparison of clinical characteristics of patients with SUR1 and Kir6.2 mutations who successfully transferred from insulin to sulfonylureas

CharacteristicSUR1 patients with successful sulfonylurea treatmentKir6.2 patients with successful sulfonylurea treatment*P
n2144
Neurological features4 (19)6 (14)0.72
Male sex8 (38)24 (55)0.16
Birth weight (g)2,700 (1,470–3,500)2,740 (1,871–3,570)0.27
Birth weight (SD score)−1.3 (−2.79 to −0.1)−1.0 (−3.7 to 1.3)0.46
Age at diagnosis (weeks)5 (0–30)6 (0–152)0.52
Age at start of sulfonylurea treatment (years)7.2 (0.2–46.5)6 (0.2–36.0)0.55
Days to transfer3.5 (1–107)12 (0–170)0.12
A1C before sulfonylurea treatment (%)7.1 (5.0–21.0)8.1 (6.3–13.1)0.062
Insulin dose (units · kg−1 · day−1)0.4 (0.2–0.9)0.7 (0.1–1.2)0.002
Equivalent dose of glyburide (mg · kg−1 · day−1)0.26 (0.07–2.8)0.45 (0.05–1.5)0.005
  • Data are median (range) or n (%) unless otherwise indicated. Data from the Kir6.2 patients are taken from ref. 14.

  • *

    * Data from Pearson et al. (ref. 14).

  • P values are for comparison of the patients with SUR1 mutations with patients with Kir6.2 mutations and were calculated by the Mann-Whitney U test or Fisher's exact test for categorical data.